Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2022-03-22 Regulatory Filings
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
Regulatory Filings Classification · 1% confidence The document is a press release dated March 22, 2022, announcing that Swissmedic (the Swiss agency for therapeutic products) has granted temporary approval for the drug Minjuvi (tafasitamab) in combination with lenalidomide for treating adults with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL). This type of announcement, detailing regulatory milestones, clinical trial results supporting the approval, and commercialization updates, is characteristic of a general corporate news release regarding product development and regulatory progress. It is not a full Annual Report (10-K), a quarterly report (IR), a formal Audit Report (AR), or a transcript (CT). Since it is a specific announcement about a regulatory event and clinical data summary, it fits best under the general category for corporate news releases that don't fit other specific financial/governance codes. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a significant, non-standard regulatory/product news announcement, although it is essentially a Media Release/Press Release. However, since there is no specific 'Press Release' or 'Regulatory Approval Announcement' code, and this is a formal announcement disseminated via news channels (indicated by DGAP-News and Media Release header), RNS serves as the best fit among the provided choices for a significant, non-financial periodic filing.
2022-03-22 English
MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Earnings Release Classification · 1% confidence The document is titled "MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update." It contains detailed financial tables and figures for Q4 2021 and the full year 2021, including revenues, expenses, operating loss, and net profit/loss, along with forward-looking financial guidance for 2022. The presence of detailed financial statements and the explicit mention of 'Full Year 2021 Financial Results' strongly indicates this is a comprehensive annual financial report, which aligns with the definition of a 10-K, even though the document itself is presented as a news release/DGAP announcement. However, since the content is the full set of annual financial results, it is classified as the Annual Report (10-K) rather than just an Earnings Release (ER) or Report Publication Announcement (RPA), given its substantial length (27k characters) and depth of financial detail covering the entire fiscal year. Q4 2021
2022-03-16 English
National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
Regulatory Filings Classification · 1% confidence The document is a 'Media Release' dated March 15, 2022, announcing an update by the National Comprehensive Cancer Network (NCCN) regarding the designation of the drug Monjuvi (tafasitamab-cxix) to a Preferred Regimen in their Clinical Practice Guidelines. It contains detailed information about the drug, safety warnings, and company boilerplate, typical of a press release announcing a positive clinical or regulatory development. It is not a formal SEC filing like a 10-K, nor is it a transcript (CT) or a formal dividend notice (DIV). Since it is a general corporate announcement disseminated via DGAP (a service often used for regulatory news and press releases), and it doesn't fit the specific categories like ER (Earnings Release), AR (Audit Report), or IP (Investor Presentation), the most appropriate general category for a significant, non-financial-result-focused corporate update that is not a specific regulatory form is 'Regulatory Filings' (RNS) as a broad announcement category, or potentially 'LTR' if it were about legal proceedings, but here it is about clinical guideline acceptance. Given the options, and that it is a news announcement about a clinical/regulatory event, RNS serves as the best fit for a general corporate news release that isn't a core financial report or management change.
2022-03-15 English
Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
Call Transcript Classification · 1% confidence The document is an announcement titled "Invitation to MorphoSys’ Full Year Results 2021 Conference Call on March 17, 2022". It explicitly states that the company "will publish its results for the financial year 2021 on March 16, 2022" and then invites recipients to the subsequent conference call to present those results. This structure—announcing the release of results and inviting participation in the discussion/Q&A—is characteristic of an Earnings Release (ER) or a precursor/announcement thereof. Since the document focuses on the conference call details for discussing the full-year results, it aligns best with the 'Call Transcript' (CT) category if it were the transcript, or the 'Earnings Release' (ER) category if it were the initial results summary. Given the context of announcing the results publication date and hosting a call to present them, it functions as the primary communication surrounding the earnings event. However, the definition for 'Call Transcript' (CT) is 'Full text transcript of company conference calls (like earnings calls with Q&A)'. This document is an *invitation* to the call, not the transcript itself. The definition for 'Earnings Release' (ER) is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. While this document announces the *timing* of the results publication, its primary focus is the conference call. Since the call itself is for presenting the results, and this document is the invitation/alert for that presentation, it is most closely related to the earnings event. If the document were just announcing the publication of the results document itself without the call details, it might be RPA. Because it centers on the conference call where results are presented, 'Call Transcript' (CT) is the closest fit for the *event* being announced, even though this specific document is the invitation. Re-evaluating the definitions: This is an invitation to the conference call where results are presented. If the actual transcript were present, it would be CT. If the key highlights of the results were present, it would be ER. Since this is an announcement *about* the earnings call, and it is not a generic regulatory filing (RNS), the most relevant category describing the *content* of the upcoming event is the one related to earnings calls. Given the options, and recognizing that this is an announcement *for* the earnings call, it is often grouped with ER or CT. Since the document mentions the results publication date and the call details, it serves as the primary earnings event announcement. I will classify it as ER, as it precedes and announces the discussion of the full-year results, which is the core financial event being communicated. If the document were shorter and only said 'Results attached', it would be RPA. Since it details the presentation event, ER is more appropriate than RPA or RNS.
2022-03-10 English
Ad hoc: MorphoSys AG reports non-cash impairment charge of 231 million on goodwill after consolidation of research and discovery functions; corresponding increase of Group operating expenses in 2021
Regulatory Filings Classification · 1% confidence The document is explicitly labeled as an "Ad-hoc" release and an "Ad hoc: MorphoSys AG reports non-cash impairment charge..." It discloses a significant, non-routine financial event (a goodwill impairment charge) that is material to the company's financial standing, released outside of standard reporting cycles (it mentions the impact will be included in the Q4 2021 results released on March 16, 2022). This type of immediate, material disclosure, often mandated by regulations like MAR (mentioned in the text: "Disclosure of an inside information acc. to Article 17 MAR"), is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were summarizing results. Since it is a specific, material, non-scheduled announcement about an accounting event rather than a full report or a standard earnings summary, RNS is the most appropriate general regulatory category for such an ad-hoc disclosure that doesn't fit the other specific financial report types (10-K, IR, ER). Given the options, RNS serves as the best fit for a mandatory, ad-hoc regulatory disclosure of inside information.
2022-03-10 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed sections regarding the 'Notification of Major Holdings' as per Article 40, Section 1 of the WpHG (German Securities Trading Act). It details the acquisition/disposal of shares with voting rights by JPMorgan Chase & Co., including specific calculations of voting rights percentages (e.g., 2.72% direct, 3.93% via instruments) and the date the threshold was crossed (17 Feb 2022). This content directly matches the definition of reporting changes in significant share ownership levels, which corresponds to the Major Shareholding Notification category (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the core content is the change in holding percentage, making MRQ more specific than DVA (Declaration of Voting Results) or RNS (General Regulatory Filing).
2022-02-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.